KRAS and ovarian carcinoma: At higher concentrations (>25 μM), DMF inhibits Nrf2, particularly in cancers with high Nrf2 activity (e.g., KRAS-mutated lung or ovarian cancers), by downregulating DJ-1, leading to increased oxidative stress and cytotoxicity.